Heterocyclic compounds and uses thereof
A method of inhibiting phosphatidyl inositol-3 kinase (PI3 kinase), comprising: contacting the PI3 kinase with an effective amount of a compound or pharmaceutically acceptable salt of the formula below, wherein the variables R 1 , R 2 , W 1 , W 2 , W 3 , W 4 , W 5 , are W 6 are defined herein.
1. A compound of the following formula:
or a pharmaceutically acceptable salt thereof, wherein
W 1 is CR 3 ;
W 2 is CR 4 ;
W 3 is N;
W 4 is N;
W 5 is CR 7 ;
W 6 is CR 8 ;
R 1 and R 2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate;
R 3 is amido of formula —C(O)N(R) 2 or —NHC(O)R, wherein R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heteroalicyclic; or wherein said (R) 2 may be taken together with the nitrogen to which they are attached to form an optionally substituted 4-, 5-, 6-, or 7-membered ring, and
R 4 , R 7 and R 8 are each hydrogen.
2. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 3 is amido of formula —C(O)N(R) 2 wherein said (R) 2 groups taken together with the nitrogen to which they are attached form a 4-, 5-, 6-, or 7-membered ring.
3. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is hydrogen and R 2 is amino.
4. The compound or pharmaceutically acceptable salt of claim 3 , wherein R 2 is NH 2 .
5. The compound or pharmaceutically acceptable salt of claim 2 , wherein R 1 is hydrogen and R 2 is amino.
6. The compound or pharmaceutically acceptable salt of claim 5 , wherein R 2 is NH 2 .
7. A compound or pharmaceutically acceptable salt of the compound, wherein the compound is selected from the group consisting of:
8. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure
9. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure
10. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure
11. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the following structure
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound or pharmaceutically acceptable salt of any one of claim 1 or 2 - 11 .